China Made Gemfibrozil Powder Pharmaceutical Chemicals CAS 25812 -30-0
China Made Gemfibrozil Powder Pharmaceutical Chemicals CAS 25812-30-0, Find details about China Gemfibrozil, Gemfibrozil Powder from China Made Gemfibrozil Powder Pharmaceutical Chemicals CAS 25812-30-0
Basic Info.
Model NO.
Frazer-Gemfibrozil
Appearance
White Powder
Shelf Life
2 Years
Storage
Keep in Cool and Dry Place
Delivery
Express 5-7 Days Arrive
Test Method
HPLC
Assay
99%
MOQ
1kg
Shipping Area
Worldwide/All Countries
CAS
25812-30-0
Mf
C16h17n7o2s
MW
371.42
Trademark
Xi′an Frazer Biotech Co., Ltd.
Transport Package
Foil Bag
Specification
99%
Origin
China
Model NO.
Frazer-Gemfibrozil
Appearance
White Powder
Shelf Life
2 Years
Storage
Keep in Cool and Dry Place
Delivery
Express 5-7 Days Arrive
Test Method
HPLC
Assay
99%
MOQ
1kg
Shipping Area
Worldwide/All Countries
CAS
25812-30-0
Mf
C16h17n7o2s
MW
371.42
Trademark
Xi′an Frazer Biotech Co., Ltd.
Transport Package
Foil Bag
Specification
99%
Origin
China
Product Desciption
China Made Gemfibrozil Powder Pharmaceutical Chemicals CAS 25812-30-0
Specification of Analysis
Introduction:
Gemfibrozil, 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid (Lopid), is a congener of clofibratethat was used first in the treatment of hyperlipoproteinemia inthe mid-1970s. Its mechanism of action and use are similar tothose of clofibrate. Gemfibrozil reduces plasma levels ofVLDL triglycerides and stimulates clearance of VLDL fromplasma. The drug has little effect on cholesterol plasma levelsbut does cause an increase of HDL.
Gemfibrozil is absorbed quickly from the gut and excretedunchanged in the urine. The drug has a plasma half-life of1.5 hours, but reduction of plasma VLDL concentration takesbetween 2 and 5 days to become evident. The peak effect of its hypolipidemic action may take up to 4 weeks to becomemanifest.
Usage
1. Used for the treatment of hyperlipidemia. The agent is suitable for treatment of severe type IV or type V hyperlipoproteinemia patients with high-risk coronary heart disease who had no response to treatments such as dietary control or weight loss. It is also applicable to type II-b hyperlipoproteinemia patients with high-risk coronary heart disease who had failed to respond to treatments such as dietary control, weight loss, or other lipid-regulating medications.
2. Used as a lipid-regulating agent. It can significantly reduce the levels of triglyceride and cholesterol in blood, and can significantly reduce very low-density lipoprotein (VLDL) levels and increase high-density lipoprotein (HDL) levels, but it has little effect on low-density lipoprotein (LDL) levels. Clinically, it can be used in patients with all types of lipid metabolism disorders, such as primary and secondary hyperlipoproteinemias, hypercholesterolemias, hypertriglyceridemias, mixed hyperlipidemias, and lipid metabolism disorders caused by diabetes. It can also be used to prevent the occurrence of myocardial infarction.
3. The product belongs to phenoxy aromatic acid antihyperlipidemics, which is a group of drugs developed on the basis of clofibrate including fenofibrate, Etofylline Clofibrate, Bijiangzhi, gemfibrozil and so on. These drugs were similar in chemical structure. Clofibrate has rather serious adverse reactions (which include elevating the occurrence of gallstone). Improved drugs are more effective than clofibrate, with mild and fewer adverse reactions.
4. A lipid-regulating drug that can reduce cholesterol and triglyceride levels in blood.
| Items | Standards | Results | |
| Appearance | White or off-white solid powder | Complies | |
| Identification | By IR | Complies | |
| By HPLC | Complies | ||
| Solubility | Soluble in DMF, sparingly soluble in THF, slightly soluble in methanol and acetonitrile, very sightly soluble in ethanol and dichloromethane, insoluble in water. | Complies | |
| Polymorphic Form | Polymorphic form 1 | Complies | |
| Melting Point | 211ºC~216ºC | 212.6ºC~214.5ºC | |
| Water Content | ≤ 0.50% | 0.12% | |
| Heavy Metals | ≤ 20ppm | Complies | |
| Residue on Ignition | ≤ 0.20% | 0.08% | |
| Related Substance | Any single impurity: ≤0.10% | 0.05% | |
| Total Impurities: ≤1.00% | 0.18% | ||
| Assay (on the anhydrous basis) | 98.0%~102.0% | 99.88% | |
| Particle Size | D90: ≤100µm | Complies | |
Introduction:
Gemfibrozil, 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid (Lopid), is a congener of clofibratethat was used first in the treatment of hyperlipoproteinemia inthe mid-1970s. Its mechanism of action and use are similar tothose of clofibrate. Gemfibrozil reduces plasma levels ofVLDL triglycerides and stimulates clearance of VLDL fromplasma. The drug has little effect on cholesterol plasma levelsbut does cause an increase of HDL.
Gemfibrozil is absorbed quickly from the gut and excretedunchanged in the urine. The drug has a plasma half-life of1.5 hours, but reduction of plasma VLDL concentration takesbetween 2 and 5 days to become evident. The peak effect of its hypolipidemic action may take up to 4 weeks to becomemanifest.
Usage
1. Used for the treatment of hyperlipidemia. The agent is suitable for treatment of severe type IV or type V hyperlipoproteinemia patients with high-risk coronary heart disease who had no response to treatments such as dietary control or weight loss. It is also applicable to type II-b hyperlipoproteinemia patients with high-risk coronary heart disease who had failed to respond to treatments such as dietary control, weight loss, or other lipid-regulating medications.
2. Used as a lipid-regulating agent. It can significantly reduce the levels of triglyceride and cholesterol in blood, and can significantly reduce very low-density lipoprotein (VLDL) levels and increase high-density lipoprotein (HDL) levels, but it has little effect on low-density lipoprotein (LDL) levels. Clinically, it can be used in patients with all types of lipid metabolism disorders, such as primary and secondary hyperlipoproteinemias, hypercholesterolemias, hypertriglyceridemias, mixed hyperlipidemias, and lipid metabolism disorders caused by diabetes. It can also be used to prevent the occurrence of myocardial infarction.
3. The product belongs to phenoxy aromatic acid antihyperlipidemics, which is a group of drugs developed on the basis of clofibrate including fenofibrate, Etofylline Clofibrate, Bijiangzhi, gemfibrozil and so on. These drugs were similar in chemical structure. Clofibrate has rather serious adverse reactions (which include elevating the occurrence of gallstone). Improved drugs are more effective than clofibrate, with mild and fewer adverse reactions.
4. A lipid-regulating drug that can reduce cholesterol and triglyceride levels in blood.
You Might Also Like
Inch Size R Series Open-Zz-2RS Deep Groove Ballbearings R144......
Dried Mealworms for Tropicl Fish
Wc67k Series Economic Type CNC Hydraulic Press Brake
White Cranked Espag UPVC Window Hardware Handle
VFD 37kw/45kw 380V Inverter Torque Control Motor Frequency I......
0.9mx9m 14mm Multiple Color PVC Coil Plastic Mat
Stainless Steel Broken Reverse Twill Dutch Weave Wire Mesh 1......
Factory Price of Sodium Pyrrolidone Carboxylate CAS 28874 -5......
60Hz 1800rpm 50kVA/40kw Perkins Engine Diesel Generator Set ......
Blue Simple Rubber Squeeze Shower Duck
Jaw Crusher Low Price Mining Crushing Machine Zhengzhou
25mm Sturdy Steel Cam Buckles Motorbike Tie-Down Straps Asse......